论文部分内容阅读
目的:评价莫西沙星注射液与阿奇霉素分散片联合治疗社区获得性肺炎的临床疗效和安全性。方法:收集90例社区获得性肺炎患者,随机分为2组进行随机对照试验。治疗组(45例)给予莫西沙星注射液,每次0.4g,静脉滴注,qd,疗程5~7d,同时口服阿奇霉素分散片,首日0.5g顿服,第2~5d,0.25g顿服。对照组给予左氧氟沙星注射液,每次0.2g,静脉滴注,b id,疗程5~7d,同时口服阿奇霉素分散片,首日0.5g顿服,第2~5d,0.25g顿服。结果:治疗结束后,治疗组临床疗效、细菌清除率与对照组比较,差异有统计学意义(P<0.05),药物不良反应发生率与对照组比较,差异无统计学意义(P>0.05)。结论:莫西沙星联合阿奇霉素治疗社区获得性肺炎临床疗效确切,且安全性高,值得临床推广使用。
Objective: To evaluate the clinical efficacy and safety of moxifloxacin injection in combination with azithromycin dispersible tablets in the treatment of community-acquired pneumonia. Methods: Ninety patients with community acquired pneumonia were randomly divided into two groups for randomized controlled trials. The treatment group (45 cases) were given moxifloxacin injection, each 0.4g, intravenous drip, qd, course of treatment 5 ~ 7d, while oral azithromycin dispersible tablets, the first day 0.5g Dayton clothes, the first 2 ~ 5d, 0.25g Dayton clothes. The control group was given levofloxacin injection, each 0.2g, intravenous infusion, b id, course of treatment 5 ~ 7d, while oral azithromycin dispersible tablets, the first day of 0.5g Dayton clothing, the first 2 ~ 5d, 0.25g Dayton clothing. Results: After treatment, the clinical curative effect and bacterial clearance rate in the treatment group were significantly different from those in the control group (P <0.05). There was no significant difference in the incidence of adverse drug reactions between the treatment group and the control group (P> 0.05) . Conclusion: Moxifloxacin combined azithromycin in the treatment of community-acquired pneumonia clinical curative effect is accurate, and high safety, it is worth to promote the use of the clinic.